Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

artificial intelligence investment

Industry Watcher’s Digest

Buzzworthy developments of the past few days.

Thumbnail

States introduce nearly 90 bills to address ‘time-wasting’ prior authorization policies

More than a dozen proposals are being considered this legislative session, as the AMA lobbies alongside radiology groups to address this issue. 

artificial intelligence federal regulation

Heard on Capitol Hill: ‘I can’t recall when we’ve had people come before us and plead with us to regulate them’

Washington has been all over AI this week. One highlight: OpenAI CEO Sam Altman testifying strongly in favor of federal AI oversight.

black woman breast cancer pink ribbon

Experts cite 'urgent need' for changes to USPSTF breast cancer screening recommendations

The USPSTF’s update suggests that women should screen every other year, but the group's own modeling studies have cited the benefits of annual screening.

framework for regulating healthcare artificial intelligence

US senators introduce legislation to strengthen payment for diagnostic imaging agents

The American College of Radiology, SNMMI and the Michael J. Fox Foundation, among others, voiced support for the FIND Act. 

Thumbnail

How age, gender and medical specialty affect a physician's risk of being sued

New data from the American Medical Association reveal that nearly one-third of physicians in the United States have been sued during their medical career. 

WHO warns against use of artificial sweeteners, highlighting CVD and diabetes risks

The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.

FDA grants fast track designation to Bayer’s new drug for preventing stroke in AFib patients

The new drug, asundexian, is currently the subject of two multicenter Phase III studies—the OCEANIC-AF trial and OCEANIC-STROKE trial—focused on its safety and efficacy.